Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

3.22USD
10:14am EST
Change (% chg)

$0.07 (+2.22%)
Prev Close
$3.15
Open
$3.18
Day's High
$3.25
Day's Low
$3.15
Volume
38,419
Avg. Vol
231,686
52-wk High
$4.51
52-wk Low
$1.08

Select another date:

Mon, Feb 12 2018

BRIEF-Catalyst Pharmaceuticals Announces Plans To Resubmit New Drug Application For Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES PLANS TO RESUBMIT NEW DRUG APPLICATION FOR FIRDAPSE®

BRIEF-Great Point Partners Reports 5.14 Pct Passive Stake In Catalyst Pharma

* GREAT POINT PARTNERS LLC REPORTS A 5.14 PERCENT PASSIVE STAKE IN CATALYST PHARMACEUTICALS INC AS OF NOV 28 - SEC FILING Source text for Eikon: (http://bit.ly/2jaVqTo) Further company coverage:

BRIEF-Catalyst Pharmaceuticals Inc Prices Previously Announced Public Offering Of Common Stock

* CATALYST PHARMACEUTICALS, INC. PRICES PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Pharma Announces Proposed Public Offering Of Common Stock

* CATALYST PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Pharma Posts Positive Top-Line Results From Second Phase 3 Clinical Trial Of Firdapse

* CATALYST PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SECOND PHASE 3 CLINICAL TRIAL OF FIRDAPSE® IN PATIENTS WITH LAMBERT-EATON MYASTHENIC SYNDROME

BRIEF-Catalyst Pharmaceuticals ‍announces phase 2 study of Firdapse

* Announces phase 2 study of Firdapse in ambulatory patients with spinal muscular atrophy​

BRIEF-Catalyst Pharmaceuticals posts Q3 loss per share $0.05

* Catalyst Pharmaceuticals announces third quarter 2017 financial results and provides corporate update

BRIEF-Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse®

* Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse® in patients with Lambert-Eaton Myasthenic Syndrome

BRIEF-Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities

* Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities

Select another date: